Grant: Master's Award: Canada Graduate Scholarships
McGill University
$27,000.00
Effect of Hydroxocobalamin Dose Escalation on Cobalamin C deficiency (cblC) Cell Lines
FY 2024-25
Summary
Vitamin B12 (cobalamin) can only be obtained from animal products or dietary supplements. Without Vitamin B12, homocysteine (an amino acid) and methylmalonic acid (an organic acid) build up in blood and urine and are toxic to the body. There are genetic defects in the metabolism of vitamin B12: the most common of these is called cblC, which is caused by mutations in the MMACHC gene. Patients with this disease have various symptoms, such as feeding difficulties, developmental delay, anemia and seizures, often in the first year of life. Hydroxocobalamin, which is a form of vitamin B12, is the most commonly available treatment. In the past 15 years, different researchers have reported that patients benefit from increasing the dose of vitamin B12 injections for patients. The reason for this improvement, however, is not known because these doses are much higher than those usually needed for the vitamin. In this project, we want to test the effect of increasing the amount of hydroxocobalamin on cultured cells from patients with known mutations in the MMACHC gene, which is causal for the cblC disease. In this case, we will measure the effect of hydroxocobalamin on the amount and function of MMACHC protein and any other possible protein involved in vitamin B12 metabolism. We make these measurements through well-established experiments, which our group has used for decades. Since our laboratory discovered the MMACHC gene and we have an extensive collection of cell lines from patients with known mutations, we are well-placed to conduct these studies.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
529999
Name
Kaviani Negar
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Effect of Hydroxocobalamin Dose Escalation on Cobalamin C deficiency (cblC) Cell Lines
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Homocysteine; Hydroxocobalamin; Inborn Error; Methylmalonic Acid; Mmachc; Vitamin B12
Abstract
Vitamin B12 (cobalamin) can only be obtained from animal products or dietary supplements. Without Vitamin B12, homocysteine (an amino acid) and methylmalonic acid (an organic acid) build up in blood and urine and are toxic to the body. There are genetic defects in the metabolism of vitamin B12: the most common of these is called cblC, which is caused by mutations in the MMACHC gene. Patients with this disease have various symptoms, such as feeding difficulties, developmental delay, anemia and seizures, often in the first year of life. Hydroxocobalamin, which is a form of vitamin B12, is the most commonly available treatment. In the past 15 years, different researchers have reported that patients benefit from increasing the dose of vitamin B12 injections for patients. The reason for this improvement, however, is not known because these doses are much higher than those usually needed for the vitamin. In this project, we want to test the effect of increasing the amount of hydroxocobalamin on cultured cells from patients with known mutations in the MMACHC gene, which is causal for the cblC disease. In this case, we will measure the effect of hydroxocobalamin on the amount and function of MMACHC protein and any other possible protein involved in vitamin B12 metabolism. We make these measurements through well-established experiments, which our group has used for decades. Since our laboratory discovered the MMACHC gene and we have an extensive collection of cell lines from patients with known mutations, we are well-placed to conduct these studies.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kaviani, Negar
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~